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Summary Background MET expression and activation ap-
pear to be important for initiation and progression of triple-
negative breast cancer. Tivantinib (ARQ 197) is an orally ad-
ministered agent that targets MET, although recent preclinical
data suggests the agent may have mechanisms of action that
are independent of MET signaling. We conducted a phase 2
study of tivantinib monotherapy in patients with metastatic
triple-negative breast cancer.Methods Patients with metastatic
triple-negative breast cancer who had received 1 to 3 prior
lines of chemotherapy in the metastatic setting were enrolled
into this two-stage, single arm phase 2 study. Treatment
consisted of twice daily oral dosing of tivantinib (360 mg po
bid) during a 21-day cycle. Patients underwent restaging scans
at 6 weeks, and then every 9 weeks. Tumor biomarkers that
might predict response to tivantinib were explored. Results 22
patients were enrolled. The overall response rate was 5 %
(95 % CI 0–25 %) and the 6-month progression-free survival
(PFS) was 5 % (95 % CI 0–25 %), with one patient achieving
a partial response (PR). Toxicity was minimal with only 5
grade ≥3 adverse events (one grade 3 anemia, one grade 3
fatigue, and 3 patients with grade 3/4 neutropenia).
Conclusion This study represents the first evaluation of
tivantinib for the treatment of metastatic triple-negative breast
cancer. These results suggest that single agent tivantinib is
well tolerated, but did not meet prespecified statistical targets
for efficacy.
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Introduction
Breast cancer is the most commonly diagnosed cancer and the
second leading cause of cancer death in American women [1].
Despite recent advances in breast cancer treatment, metastatic
disease remains incurable. One possible limitation of current
therapies has been an inability to select subsets of patients
most likely to benefit from specific agents. With the applica-
tion of gene expression array technology, the heterogeneity of
breast cancer has become clearer and the identification of
novel cancer subtypes has reinvigorated the search for more
specific and effective treatments. Hierarchical clustering of
genomic expression data from breast cancer specimens has
demonstrated several distinct tumor subgroups with unique
expression profiles, including a HER2-positive subgroup,
two estrogen-receptor (ER) driven groups, and a “basal-like”
group [2]. The basal-like tumors have a poor prognosis rela-
tive to other subtypes, even with the best available therapy.
Approximately 10–15 % of individuals with breast cancer
have basal-like disease [3]. While not all basal-like cancers
are triple-negative breast cancers, the majority of triple-
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negative breast cancers have a basal-like phenotype. There are
currently no U.S. Food and Drug Administration (FDA)-ap-
proved agents for specific management of triple-negative
breast cancer, and there is significant need to develop rational
therapy for this subtype of the disease.
MET is a membrane receptor normally expressed on cells
of epithelial origin. Hepatocyte growth factor (HGF) is the
only known ligand of the MET receptor. Upon HGF stimula-
tion, MET induces several biologic responses that lead to in-
vasive growth. MET overexpression, with or without gene
amplification, has been reported in a variety of malignancies,
including breast, colorectal, lung, gastric, and hepatocellular
carcinoma [4, 5]. Elevated expression of MET has been asso-
ciated with poor prognosis in breast cancer [6, 7].
Interestingly, data suggest that hepatocyte growth factor
(HGF), the ligand for MET, andMETare expressed to a great-
er degree in triple-negative breast cancer relative to other
breast cancer subtypes [8–11]. Mouse models also suggest a
critical role for the MET pathway during the development of
triple-negative breast cancer. Mice harboring an activating
mutantMET knock-in or mutantMET transgene under mouse
mammary tumor virus promoter, develop breast cancers with
a triple-negative phenotype [12, 13]. Additionally, a MET-
driven pathway gene expression signature clustered with basal
and triple-negative breast cancer from human tissue samples
and correlated with worse patient outcome [12, 13]. These
studies suggest that METexpression and activation are impor-
tant for initiation and progression of triple-negative breast
cancer.
Early preclinical work suggested that tivantinib (ARQ 197)
binds to and inhibitsMET in vitro, and phase I and II trials in a
variety of malignancies demonstrated the safety and tolerabil-
ity of tivantinib, and suggested promising activity of this agent
[14–17]. Because MET expression is increased in the triple-
negative subset of breast cancer and is associated with worse
prognosis, targeting MET signaling in this population is a
rational therapeutic strategy. We therefore conducted a
single-arm phase 2 study of tivantinib monotherapy in unse-
lected patients with metastatic triple-negative breast cancer.
Patients and methods
Patient eligibility
Patients ≥18 years of age with measurable metastatic triple-
negative breast cancer were eligible. Triple-negative status
was defined as estrogen receptor negative (<10 % staining
by immunohistochemistry (IHC)), progesterone receptor neg-
ative (<10 % staining by IHC), and HER2-negative (0 or 1+
by IHC, or FISH <2.0). Patients may have received 1 to 3 prior
chemotherapeutic regimens for metastatic breast cancer, and
must have been off treatment for 14 days prior to initiation of
study treatment. Patients must have recovered from acute tox-
icities of their prior treatment. Patients may have received
prior radiation therapy in either the metastatic or early-stage
setting, but radiation was required to be completed at least
14 days prior to initiation of study treatment. Patients were
required to have an Eastern Cooperative Oncology Group
(ECOG) performance status ≤2, and a projected life expectan-
cy greater than 6 months. They were also required to provide
formalin-fixed, paraffin-embedded (FFPE) tumor tissue. Key
exclusion criteria included: prior receipt of a MET inhibitor;
known brain metastases that are untreated, symptomatic, or
require therapy to control symptoms; and QTc>470 ms.
Research was approved by local human research protections
programs and institutional review boards, and studies were
conducted in accordance with the Declaration of Helsinki.
Study design and treatment
This was a single-arm, two-stage phase 2 study assessing the
efficacy of tivantinib monotherapy in patients with metastatic
triple-negative breast cancer. Tivantinib was provided by
Daiichi Sankyo/ArQule through the Cooperative Research
and Development Agreement (CRADA) program. Treatment
consisted of oral dosing of tivantinib at 360 mg twice daily
over a 21-day cycle. Patients underwent radiographic
restaging at 6 weeks, and then every 9 weeks. Patients with
complete or partial RECIST responses continued to receive
study treatment, while those with progressive disease were
taken off study. Dose reductions for toxicity occurred if pa-
tients experienced grade 3 or 4 neutropenia or non-
hematologic adverse events. From the starting dose of
360 mg, doses were reduced as needed to 240 mg twice daily,
120 mg twice daily, and 120 mg once daily.
The primary objective of this study was to evaluate the
activity of tivantinib, as defined by 6-month progression-free
survival (PFS) in patients with metastatic triple-negative
breast cancer. The 6-month progression-free survival (PFS)
was defined as the proportion of patients still receiving treat-
ment at 6 months, who were alive and free of progression at
this time point. Secondary objectives were to evaluate objec-
tive response based on RECIST 1.1 criteria, to evaluate MET
and phospho-MET expression in archival tumor tissue, and to
evaluate the incidence ofMET positive circulating tumor cells
(CTCs) at baseline.
Assessment of MET amplification by fluorescence in situ
hybridization (FISH) in tissue
MET FISH probe labeled with SpectrumRed and CEP7 refer-
ence probe labeled with SpectrumGreen were purchased from
Abbott Molecular (Des Plaines, IL). FISH was performed fol-
lowing standard protocols. Briefly, 5 μm tissue slides were
baked overnight at 60 °C, deparaffinized, treated in 1 %
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sodium borohydride for 4 h and heated in pressure cooker for
20 min in citrate buffer (pH=6). After treatment with
150 μg/ml solution of Proteinase K, slides were fixed in 1 %
neutral-buffered formalin and denatured in 70 % formamide
for 4 min at 72 °C. Probe was denatured for 5 min at 80 °C and
incubated for 30min at 37 °C for pre-annealing. Hybridization
was carried out overnight at 37 °C; post-hybridization slide
washes were carried out for 20 min in 50 % formamide/
2xSSC at 45 °C, followed by 5 min wash in 1×SSC at
45 °C. FISH signal evaluation and acquisition were performed
manually using filter sets and software developed by Applied
Spectral Imaging (Carlsbad, CA). Several fields with at least
50 tumor cells total were captured and ratio of MET to CEP7
signal numbers was calculated. Assessment of ploidy status
was done by visual screening of all tumor area; cells with
maximum number of signals were recorded. MET amplifica-
tion was defined as a MET/CEP7 ratio≥2. Samples having a
MET/CEP7 ratio from 1.5 and up to 2 were defined as having
relative MET gain. Samples with a MET/CEP7 ratio of 1 but
with more than two copies of each probe were defined as
having polysomy of chromosome 7.
Assessment of MET amplification in circulating tumor
cells
CTCswere enriched from 7.5 mL of a patient’s whole blood at
the Circulating Tumor Cell Core Facility (Brigham and
Women’s Hospital, Boston, MA) using the Circulating
Tumor Cell Profile Kit (Veridex/Janssen Diagnostics,
Raritan, NJ). Processed samples were received as cells
suspended in 900 uL of buffer. An equal volume of PBS
was added before tubes were spun down at 200×g for
8 min. Supernatant was carefully removed, leaving approxi-
mately 60 uL of buffer. Cell pellets were gently resuspended
and the suspension was applied on the labeled slide and
allowed to dry in the vacuum desiccators at room temperature.
Slides were placed in methanol at −20 °C for aging and
storage.
For FISH, dried slides were treated in 2×SSC at 37 °C for
30 min, followed by 10 min of treatment with 0.002 % pepsin
solution in 0.01M HCl at 37 °C and 15 min of fixation in 1 %
formalin at room temperature. Slides were dehydrated in the
series of ethanols, dried and co-denatured with MET/CEP7
FISH probe (Kreatech/Leica Microsystems Inc., Buffalo
Grove, IL) on an 80 °C plate for 2 min. Hybridization was
carried out at 37 °C overnight, followed by a 0.4xSSC/0.3 %
Igepal wash at 72 °C for 3 min and a 2×SSC/0.1 % Igepal
wash at room temperature for 1 min. Slides were dehydrated
in the series of ethanols, and dried before application of
Vectashield mounting medium with DAPI (Vector
Laboratories Inc., Burlingame, CA). FISH signal evaluation
and acquisition were performed manually using filter sets and
software developed by Applied Spectral Imaging (Carlsbad,
CA).
Immunohistochemistry biomarker assays
Available archival tumor tissue was tested centrally for MET
and phospho-MET protein expression. Four-micrometer-thick
sections were baked at 37 °C overnight, then deparaffinized
and rehydrated. Endogenous peroxidase activity was blocked
with 3 % hydrogen peroxide in methanol. For heat induced
epitope retrieval, slides were placed in 10 mmol/L citrate buff-
er at a pH of 6.0 (Target Retrieval Solution, S1699, DAKO)
and then pressure cooked (Biocare Medical, Concord, CA) at
122 °C to between 14 and 17 psi with the cycle lasting, on
average, 45 min and a cool-down period of approximately
20 min. Immunostains were performed on an automated in-
strument (DAKO Autostainer Plus, DAKO). A range of titers
was tested for both antibodies, and titers were calibrated using
positive control staining. Primary antibodies to MET, clone
SP44 (dilution 1:100; Spring Bioscience), phospo-MET, clone
Y1234/1235 (dilution 1:50; Cell Signaling) were incubated
for 40 min at room temperature. A DAKO polymer secondary
antibody system was used (EnVision+System-HRP; DAKO,
Carpinteria, CA) and incubated for 30 min in a humid cham-
ber at room temperature. Sections were developed using 3,3-
diaminobenzidine (Sigma Chemical, St Louis, MO) as sub-
strate and counterstained with Mayer hematoxylin. External
positive controls were also run.
MET and phospho-MET protein expression levels were
recorded as percentages of positively stained tumor cells in
each of the five intensity categories denoted as zero (no stain-
ing), 1+ (weak but detectable), 2+ (mildly distinct), 3+ (mod-
erately distinct) and 4+ (strong). For each tumor, a value was
derived by summing up the percentages of cells staining at
each intensity, multiplied by the weighted intensity of stain-
ing: H-Score=(0×% at 0)+(1×% at 1+)+(2×% at 2+)+(3×%
at 3+). This score produces a continuous variable that ranges
from 0 to 300. A positive result was set to an H-Score of 1,
defined as a minimum of 1 % of tumor cells staining weakly
1+ [18].
Whole exome sequencing protocol
In the patient who achieved a RECIST response, tumor and
matched germline tissue underwent DNA extraction and
whole exome sequencing, using a previously described proto-
col [19]. After whole exome sequencing, somatic point muta-
tions were identified usingMuTect [20]. A heuristic algorithm
was then applied to identify somatic variants that may have
clinical or biological relevance for the selected patient
samples.
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Statistical methods
This study used a Simon optimal two-stage design to control
type I error at 10 % and have at least 90 % power to detect the
acceptable response rate. The sample size was calculated to
distinguish between a response rate of 10 versus 31 %. In the
study design, 13 participants were to be enrolled in the first
stage. If there were at least 2 participants who were alive and
progression free at 6 months, the study would enroll another
13 participants. If there were 4 or fewer of the 26 who were
alive and progression-free at 6 months, the regimen would be
declared inactive. If there were 5 or more who were alive and
progression-free at 6 months, the regimen would be declared
active. PFS and 95 % confidence intervals (CIs) are described
using Kaplan-Meier methods. The overall response is tabulat-
ed. All correlative analyses are exploratory.
Results
The study was activated in April 2012. Based on slow accrual
and external findings suggesting that tivantinib may not actu-
ally inhibit MET [21], accrual to the study closed in July 2013
after a total of 22 patients were enrolled.
Patient characteristics
The baseline characteristics of the patients enrolled into the
study are listed in Table 1. The mean age was 55 and patients
had received a median of 2 prior lines of chemotherapy for
metastatic disease. Most patients had widespread metastatic
disease, with 73 % of participants having at least 3 metastatic
sites, the most common of which were regional lymph nodes
(14 of 22 patients), ipsilateral skin of breast/chest wall (11 of
22 patients), bone (10 of 22 patients) and lung (10 of 22
patients).
Response to therapy
In all patients, the median progression-free survival (PFS) was
1.2 months (95 % CI: 1.0–1.4), Fig. 1. Only one patient had
PFS>6 months (4.5 %, 95 % CI: 0.2–24.7 %). This patient
had disease involving her chest wall, lymph nodes, and pleura.
She had a progression free interval of 7.8 months, and pro-
gression occurred at a regional lymph node. This patient also
achieved a partial reponse (PR). Although the study did not
meet the prespecified threshold for continuation, the observa-
tion of one partial responder with a PFS>6 months led the
study team to continue accrual to the second stage to further
characterize the activity. The overall response rate was 4.5 %
(95 % CI 0.1–22.8 %) (Table 2). There were 6 patients
(27.3 %) with stable disease as the best overall response by
RECIST 1.1. Based on external findings about the mechanism
of action of tivantinib [21], and the fact that only 1 patient
achieved a PFS>6 months, accrual to the study closed in
July 2013 after a total of 22 patients were enrolled.
Toxicity
Few severe adverse events were reported by patients taking
tivantinib (Table 3). Of the 46 adverse events reported, 41
were of grade 1 or 2. The most common adverse event was
fatigue. There were only 5 grade ≥3 adverse events (one grade
3 anemia, one grade 3 fatigue, and 3 patients experienced
grade 3/4 neutropenia).
Table 1 Baseline patient characteristics
Characteristic Number Percent
Age
Mean (SD) 55 (10) –
Median (Range) 56 (33–73) –
Race
White 20 91
Black or African American 2 9











Fig. 1 Progression-free survival curves depicting final response to
therapy
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Four dose reductions occurred in 2 patients due to neutro-
penia and fatigue. Three of four dose reductions occurred
within the first two cycles. The one responder required two
dose reductions, one in cycle 2 (neutropenia) and another in
cycle 8 (neutropenia and fatigue).
MET expression studies
All 22 enrolled patients had adequate amounts of archival
tissue for immunohistochemical (IHC) staining. Among those
22 patients, 10 had positive IHC staining for MET (H-score:
median 5, range 1–35), while none of the patients had positive
phospho-MET staining on archival tumor tissue. Of 7 patients
with circulating tumor cells (CTCs) collected at baseline, 1
had 2-fold MET amplification in her CTCs as assessed by
FISH, but this was not correlated with response, as the patient
had progressive disease at the first 6 week restaging. Of 18
patients who had FISH testing for MET on archival tissue, 3
were amplified in <5 % of nuclei. Four patients did not have
adequate amounts of archival tissue for FISH analysis. The
one responder was negative for MET and phospho-MET by
IHC on archival tissue, and had CTCs that were not MET-
amplified. Her archival tumor tissue was amplified for MET
by FISH in less than 2 % of nuclei, though the clinical signif-
icance of this is unclear (Fig. 2).
Whole exome sequencing
Whole exome sequencing of archival tumor tissue and tissue
from time of progression in the patient who experienced a PR
was attempted. The mean target coverage of the progresion
tumor sample was 117 ×. In this sample, somatic mutations in
known breast cancer genes MAP2K4 (H79R) and TP53
(R110P) were identified, as well as a variant of unknown
significance in the kinase domain of JAK2 (E577Q). No al-
terations that suggest a mechanism of response or resistance to
this agent were found. Unfortunately, this patient’s baseline
tumor was unevaluable using this sequencing technology, so it
was not possible to determine whether any changes in muta-
tional status led to development of tivantinib resistance.
Discussion
This trial represents the first study of tivantinib for the treat-
ment of metastatic triple-negative breast cancer. Of 22 patients
that were evaluated, only one patient had an objective re-
sponse. The single responder did not have evidence of MET
expression by IHC or clear evidence of MET amplification in
her archival tumor specimen, so it is unclear if her response
was due to inhibition of MET. To further understand the mo-
lecular rationale for the one responder to tivantinib in our trial,
we performed whole exome sequencing on tissue from her
post-progression biopsy. This analysis identified mutations
in known breast cancer genes MAP2K4 and TP53, as well
as a mutation in the kinase domain of JAK2. However, the
patient’s archival tumor tissue sample was unevaluable, so we
could not compare the mutational profile of tivantinib-
sensitive versus resistant tissue.
One potential explanation for the low response rate seen in
this study was that the population was not enriched for pa-
tients with tumors that were high in MET overexpression.
Prospective data from studies of tivantinib in the treatment
of hepatocellular carcinoma found that positive MET expres-
sion (≥2+ staining in ≥50 % of tumor cells by IHC) was
associated with improved overall survival (OS), PFS, and time
to progression [22]. Additionally, in the MARQUEE trial for
patients with advanced non-small cell lung cancer, an explor-
atory analysis found that patients with tumor that were at least
2+ positive for MET by IHC in more than 50 % of tumor cell
experienced longer PFS and OS with combined MET-EGFR
inhibition while in patients with MET-low tumors, tivantinib
did not improve OS compared to placebo [23]. These data
suggest that benefit from tivantinib may potentially be
Table 2 Response rates to tivantinib therapy
Best overall response Number Percent
Partial response 1 4.5
Stable disease 6 27.3
Progressive disease 15 68.2
Table 3 Maximum grade
reported for agent specific
adverse events
Adverse events Grade 1 Grade 2 Grade 3 Grade 4 Total # of patients (%)
Fatigue 10 5 1 0 16 (73 %)
Nausea 7 0 0 0 7 (32 %)
Anemia 2 3 1 0 6 (27 %)
Diarrhea 4 2 0 0 6 (27 %)
Neutropenia 2 0 2 1 5 (23 %)
Anorexia 2 2 0 0 4 (18 %)
Rash maculo-papular 3 0 0 0 3 (14 %)
Vomiting 2 0 0 0 2 (9 %)
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restricted largely to patients with significant METoverexpres-
sion, and none of the patients in our study had MET
overexpressed in greater than 50 % of the tumor. This may
be because MET expression diminishes over time after slides
have been cut from paraffin-embedded blocks [24]. For all our
patients, samples were analyzed in batch at the end of the
clinical trial. Therefore false negativity of samples tested in
this study cannot be excluded. Alternatively, it may also be
that this level ofMEToverexpression is uncommon in TNBC.
In a randomized phase 2 study evaluating onartuzumab, a
monoclonal antibody directed against MET, only 12 % of
patients with TNBC had moderate to high expression of
MET (IHC 2+/3+ in 50 % of stained tumor cells) [25].
Interestingly, the addition of onartuzumab to either paclitaxel
and bevacizumab or paclitaxel alone did not improve PFS or
OS compared with paclitaxel and bevacizumab in patients
with metastatic or locally recurrent TNBC; additionally, the
efficacy in the MET-positive and MET-negative subgroups
was similar.
The low response rate in this study may also be related to
the possibility that tivantinib may not be a specific inhibitor of
MET. Pre-clinical work has revealed that tivantinib binds to
MET in vitro, in vivo, and demonstrated disease regression in
phase I, II, and III clinical trials [14–17]. However, while the
current study was ongoing, several preclinical studies were
published suggesting that tivantinib’s mechanism of action
may be via anti-tubulin cytotoxic activity. Basilico et al.
[26], Katayama et al. [27], and Calles et al. [28] compared
the pharmacological profile of tivantinib with that of other
selective MET inhibitors in a large panel of human tumor
cell lines. They found that tivantinib indiscriminately
caused cell death on all actively mitotic tumor cells, re-
gardless of MET gene copy number and MET protein
expression. Tivantinib also induced apoptosis in both
MET-negative tumor cells and genetically engineered can-
cer cells expressing a MET protein lacking the tivantinib-
binding domain, suggesting that tivantinib acts indepen-
dently of its ability to bind MET [26]. More recently, data
suggests that cytoskeletal and apoptotic changes in cells
treated with tivantinib may be mediated by paxilin, a cy-
toskeleton regulator controlled by MET [3].
While the reason for the low response rate seen in this study
is not clear, our results indicate that though tivantinib is well
tolerated, it does not have significant clinical efficacy when
used as monotherapy to treat unselected, metastatic triple-
negative breast cancer.
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